Outcomes for patients with high-grade glioma remain poor. Temozolomide (TMZ) is the only drug approved for first-line treatment of glioblastoma multiforme, the most aggressive form of glioma. Chronotherapy highlights the potential benefit of timed TMZ administration. This is based on pre-clinical studies of enhanced TMZ-induced glioma cytotoxicity dependent on circadian, oscillating expression of key genes involved in apoptosis, DNA damage repair, and cell-cycle mediated cell death. The current systematic review’s primary aim was to evaluate the efficacy and toxicity of TMZ chronotherapy. A systemic review of literature following PRISMA guidelines looking at clinical outcomes on TMZ chronotherapy on gliomas was performed. The search in the English language included three databases (PubMed, EMBASE, and Cochrane) and five conferences from 1946 to April 2022. Two independent reviewers undertook screening, data extraction, and risk-of-bias assessment. A descriptive analysis was conducted due to limited data. Of the 269 articles screened, two unique studies were eligible and underwent abstraction for survival and toxicity findings. Both studies—one a retrospective cohort study (n = 166) and the other a prospective randomized feasibility study (n = 35)—were conducted by the same academic group and suggested a trend for improved overall survival, but possibly increased toxicity when TMZ was administered in the morning (vs. evening). There was limited evidence suggesting possible therapeutic value from administering TMZ in the morning, which may be consistent with the pre-clinical observations of the importance of the timing of TMZ administration in vitro. Larger, pragmatic, prospective randomized controlled trials are needed to ascertain the value of TMZ chronotherapy to provide optimized and equitable care for this population.
Routine antibiotic prophylaxis against pneumocystis jirovecii pneumonia (PJP) is recommended during concurrent temozolomide and radiotherapy (TMZ-RT) for glioma based on early small studies. However, true PJP risk may be far lower, raising questions about the value and harms of universal prophylaxis. We conducted a systematic review (PROSPERO: CRD42021292396) of studies reporting PJP incidence among glioma patients treated with TMZ-RT. MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to May 1, 2025. Outcomes included overall PJP incidence and rates stratified by prophylaxis, corticosteroid exposure, and lymphopenia. Of 3791 records, 35 studies (13,637 patients, 12,301 received TMZ-RT) met eligibility criteria. Across 24 studies confirming PJP, 71 cases occurred among 12,056 TMZ-RT patients—a pooled incidence of 0.74% (95% CI, 0.59–0.93%) with minimal heterogeneity (Q = 23.3, p = 0.44; I2 = 1.4%). Seventeen studies detailed prophylaxis: 55.1% (2942/5341) of patients received it; PJP incidence was 0.8% (14/1765) with versus 0.3% (9/2719) without prophylaxis. Baseline corticosteroid exposure was reported in 13 studies (n = 5908: median 49.5%, range 27.3%–82.3%), and grade 3–4 lymphopenia in 15.2% (319/2102) of TMZ-RT patients. Incomplete study-level reporting precluded robust risk factor-adjusted analyses. Across heterogeneous populations and study designs, the pooled PJP incidence associated with TMZ-RT was 0.74% (95% CI, 0.59–0.93%). Due to the heterogeneity in study populations and designs, lack of standardized diagnostic confirmation, and incomplete reporting of steroid administration, this finding should be interpreted with caution. Currently available evidence suggests the risk of PJP is lower than the commonly cited 3.5% threshold for prophylaxis. Well-designed prospective studies are needed to clarify true infection risk and inform prophylaxis decisions. The Deanship of Graduate Studies and Scientific Research at 10.13039/501100007414 Qassim University provided financial support for the article processing charge (APC) of this manuscript.
A 19-month-old (17 months corrected) girl presented to the emergency department during the winter with sudden onset of gait ataxia. One day before presentation, upon awaking from a nap, she began to stumble and fall when running. There was no history of gross behavioural/cognitive alteration, toxic ingestion, or prodromal/active infectious illness within the past month. Furthermore, there were no symptoms of episodic ataxia, seizures, hypotonia, dysmetria, nystagmus, or myoclonus. The child was born at 31 weeks gestational age from an uncomplicated twin pregnancy. After mild transient tachypnea of the newborn and slow growth, she remained in the neonatal intensive care unit for 1 month. She...